Neogen Q1 FY2027: Revenue Up 6.5%, Operating Loss Narrows to $1.8M, Genomics Sale Still Pending
NEOG has more than doubled off its 52-week low of $5.37 on elevated volume (4.2× avg).
Summary
Neogen's Q1 FY2027 10-Q shows revenue up 6.5% to $222.8M, operating loss narrowing to $1.8M from $16.1M, and debt reduced by $20M. The $160M Genomics divestiture to Zoetis remains pending extended regulatory review.
Key Events · Earnings and Guidance · NEOG
-
Q1 Revenue Up 6.5%
Total revenue reached $222.8M, up from $209.2M, driven by Food Safety growth of 7.3% and Animal Safety growth of 4.4%.
-
Operating Loss Narrows Sharply
Operating loss improved to $1.8M from $16.1M a year ago. Segment operating income more than doubled to $23.8M, with Food Safety up 126.4% to $16.3M.
-
Gross Margin Expands 200 bps
Gross margin rose to 47.4% from 45.4%, driven by volume increases, price increases, and favorable foreign currency impacts.
-
Debt Reduced by $20M
Company made $20M in term loan prepayments in Q1 and an additional $10M in September 2026. No required principal payments until Q3 FY2029.
Analysis · NEOG · Life Sciences
Neogen's Q1 FY2027 10-Q confirms the revenue growth and guidance raise announced yesterday, but adds critical detail: segment operating income more than doubled, gross margin expanded 200 basis points to 47.4%, and the company reduced debt by $20M in the quarter with no required principal payments until FY2029. The pending $160M Genomics sale to Zoetis faces extended regulatory review in Australia and New Zealand, now expected to conclude by end of December 2026. The FDA Warning Letter on the Hycoat recall and ongoing product liability litigation remain unresolved overhangs, though the company believes losses are not material.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 29% of the 1648 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEOG was trading at $11.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $5.37 to $14.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.